Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Common Equity (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Common Equity for 5 consecutive years, with $70.1 million as the latest value for Q4 2025.

  • For Q4 2025, Common Equity fell 40.07% year-over-year to $70.1 million; the TTM value through Dec 2025 reached $70.1 million, down 40.07%, while the annual FY2025 figure was $70.1 million, 40.07% down from the prior year.
  • Common Equity hit $70.1 million in Q4 2025 for Kezar Life Sciences, down from $83.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $297.4 million in Q2 2022 and bottomed at $70.1 million in Q4 2025.
  • Average Common Equity over 5 years is $173.8 million, with a median of $159.9 million recorded in 2024.
  • Year-over-year, Common Equity skyrocketed 137.02% in 2022 and then tumbled 40.07% in 2025.
  • Kezar Life Sciences' Common Equity stood at $196.9 million in 2021, then skyrocketed by 37.08% to $269.9 million in 2022, then plummeted by 30.5% to $187.6 million in 2023, then crashed by 37.67% to $116.9 million in 2024, then crashed by 40.07% to $70.1 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $70.1 million, $83.0 million, and $91.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.